Cargando…

The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients

Backgrounds: Angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and thiazide diuretics (TD) are common antihypertensive drugs for diabetes patients with hypertension. The purpose of this study was to compare the cardiovascular risks of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ming, Lin, Wenrui, Ma, Tianqi, Luo, Yi, Xie, Hejian, Cheng, Xunjie, Bai, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655533/
https://www.ncbi.nlm.nih.gov/pubmed/36362714
http://dx.doi.org/10.3390/jcm11216486
_version_ 1784829209302007808
author Gao, Ming
Lin, Wenrui
Ma, Tianqi
Luo, Yi
Xie, Hejian
Cheng, Xunjie
Bai, Yongping
author_facet Gao, Ming
Lin, Wenrui
Ma, Tianqi
Luo, Yi
Xie, Hejian
Cheng, Xunjie
Bai, Yongping
author_sort Gao, Ming
collection PubMed
description Backgrounds: Angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and thiazide diuretics (TD) are common antihypertensive drugs for diabetes patients with hypertension. The purpose of this study was to compare the cardiovascular risks of these drugs in patients with isolated systolic hypertension (ISH) and type 2 diabetes mellitus (T2DM). Methods: We used Action to Control Cardiovascular Risk in Diabetes trial data to explore the relationship between antihypertensive drugs and cardiovascular risks in ISH with T2DM patients by performing propensity score matching, Kaplan–Meier survival analyses and Cox proportional regression. Results: The cumulative incidence rates of primary outcomes (PO, including cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke) in the ARB use group were significantly lower than those without (hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.34–0.83; p = 0.006). However, for ACEI, CCB and TD, they were negligible (ACEI: p = 0.209; CCB: p = 0.245; TD: p = 0.438). ARB decreased cardiovascular mortality (CM) in PO rather than non-fatal myocardial infarction (NMI) and non-fatal stroke (NST) (CM: HR 0.32; 95%CI 0.18–0.90; p = 0.004; NMI: p = 0.692; NST: p = 0.933). Conclusion: ARB may alleviate the cardiovascular risks in ISH with T2DM patients, but ACEI, CCB, and TD did not.
format Online
Article
Text
id pubmed-9655533
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96555332022-11-15 The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients Gao, Ming Lin, Wenrui Ma, Tianqi Luo, Yi Xie, Hejian Cheng, Xunjie Bai, Yongping J Clin Med Article Backgrounds: Angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and thiazide diuretics (TD) are common antihypertensive drugs for diabetes patients with hypertension. The purpose of this study was to compare the cardiovascular risks of these drugs in patients with isolated systolic hypertension (ISH) and type 2 diabetes mellitus (T2DM). Methods: We used Action to Control Cardiovascular Risk in Diabetes trial data to explore the relationship between antihypertensive drugs and cardiovascular risks in ISH with T2DM patients by performing propensity score matching, Kaplan–Meier survival analyses and Cox proportional regression. Results: The cumulative incidence rates of primary outcomes (PO, including cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke) in the ARB use group were significantly lower than those without (hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.34–0.83; p = 0.006). However, for ACEI, CCB and TD, they were negligible (ACEI: p = 0.209; CCB: p = 0.245; TD: p = 0.438). ARB decreased cardiovascular mortality (CM) in PO rather than non-fatal myocardial infarction (NMI) and non-fatal stroke (NST) (CM: HR 0.32; 95%CI 0.18–0.90; p = 0.004; NMI: p = 0.692; NST: p = 0.933). Conclusion: ARB may alleviate the cardiovascular risks in ISH with T2DM patients, but ACEI, CCB, and TD did not. MDPI 2022-11-01 /pmc/articles/PMC9655533/ /pubmed/36362714 http://dx.doi.org/10.3390/jcm11216486 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gao, Ming
Lin, Wenrui
Ma, Tianqi
Luo, Yi
Xie, Hejian
Cheng, Xunjie
Bai, Yongping
The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
title The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
title_full The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
title_fullStr The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
title_full_unstemmed The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
title_short The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
title_sort impact of different antihypertensive drugs on cardiovascular risk in isolated systolic hypertension with type 2 diabetes patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655533/
https://www.ncbi.nlm.nih.gov/pubmed/36362714
http://dx.doi.org/10.3390/jcm11216486
work_keys_str_mv AT gaoming theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT linwenrui theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT matianqi theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT luoyi theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT xiehejian theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT chengxunjie theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT baiyongping theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT gaoming impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT linwenrui impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT matianqi impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT luoyi impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT xiehejian impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT chengxunjie impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients
AT baiyongping impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients